These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7623616)

  • 1. Safety and tolerability of CI-979 in patients with Alzheimer's disease.
    Sramek JJ; Sedman AJ; Reece PA; Hourani J; Bockbrader H; Cutler NR
    Life Sci; 1995; 57(5):503-10. PubMed ID: 7623616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
    Cutler NR; Sramek JJ
    Eur J Clin Pharmacol; 1995; 48(6):421-8. PubMed ID: 8582458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S; Peters J; Rock A; Pavliv L
    Clin Ther; 2009 Sep; 31(9):1922-35. PubMed ID: 19843482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease.
    Sramek JJ; Viereck C; Huff FJ; Wardle T; Hourani J; Stewart JA; Cutler NR
    Life Sci; 1995; 57(12):1241-8. PubMed ID: 7674813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
    Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR
    Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
    Sramek JJ; Forrest M; Mengel H; Jhee SS; Hourani J; Cutler NR
    Life Sci; 1998; 62(3):195-202. PubMed ID: 9488097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
    Cutler NR; Sramek JJ; Murphy MF; Nash RJ
    Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metrifonate for Alzheimer's disease.
    López-Arrieta JM; Schneider L
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease.
    Sedman AJ; Bockbrader H; Schwarz RD
    Life Sci; 1995; 56(11-12):877-82. PubMed ID: 10188788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease.
    Cutler NR; Shrotriya RC; Sramek JJ; Veroff AE; Seifert RD; Reich LA; Hironaka DY
    Ann N Y Acad Sci; 1993 Sep; 695():332-6. PubMed ID: 8239308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NXX-066 in patients with Alzheimer's disease: a bridging study.
    Sramek JJ; Hourani J; Jhee SS; Cutler NR
    Life Sci; 1999; 64(14):1215-21. PubMed ID: 10210264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
    Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
    J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
    Sramek JJ; Cutler NR; Hurley DJ; Seifert RD
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):85-91. PubMed ID: 7535938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
    Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
    Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease.
    Trollor JN; Sachdev PS; Haindl W; Brodaty H; Wen W; Walker BM
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):616-25. PubMed ID: 16958947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.